Clement G Yedjou

Jul 21, 2023 | frontiersin.org | Di Zhou |Clement G Yedjou |Nicholas Pavlidis |Ralf Küppers

IntroductionDuring the last three decades, substantial progress has been made in the prevention, early diagnosis, and treatment of malignancies. Advances in early detection and effective treatment have significantly improved overall survival in patients with malignant tumors, such as proteomics used in ovarian cancer (1). The five-year survival rate for all cancers is nearly 40.5% in China and 68% the United States (2, 3).